DE69835524D1 - Ein verfahren zur inhibierung der komplementaktivierung über einen alternativen weg - Google Patents

Ein verfahren zur inhibierung der komplementaktivierung über einen alternativen weg

Info

Publication number
DE69835524D1
DE69835524D1 DE69835524T DE69835524T DE69835524D1 DE 69835524 D1 DE69835524 D1 DE 69835524D1 DE 69835524 T DE69835524 T DE 69835524T DE 69835524 T DE69835524 T DE 69835524T DE 69835524 D1 DE69835524 D1 DE 69835524D1
Authority
DE
Germany
Prior art keywords
complement activation
alternative way
inhibiting complement
inhibiting
activation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69835524T
Other languages
English (en)
Other versions
DE69835524T2 (de
Inventor
Rekha Gupta-Bansal
R Brunden
James B Parent
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Fremont Inc
Original Assignee
Amgen Fremont Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Fremont Inc filed Critical Amgen Fremont Inc
Application granted granted Critical
Publication of DE69835524D1 publication Critical patent/DE69835524D1/de
Publication of DE69835524T2 publication Critical patent/DE69835524T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Fats And Perfumes (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Cereal-Derived Products (AREA)
  • External Artificial Organs (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69835524T 1997-08-26 1998-08-24 Ein verfahren zur inhibierung der komplementaktivierung über einen alternativen weg Expired - Fee Related DE69835524T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91834997A 1997-08-26 1997-08-26
US918349 1997-08-26
PCT/US1998/017500 WO1999010009A1 (en) 1997-08-26 1998-08-24 A process for inhibiting complement activation via the alternative pathway

Publications (2)

Publication Number Publication Date
DE69835524D1 true DE69835524D1 (de) 2006-09-21
DE69835524T2 DE69835524T2 (de) 2007-04-05

Family

ID=25440234

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69835524T Expired - Fee Related DE69835524T2 (de) 1997-08-26 1998-08-24 Ein verfahren zur inhibierung der komplementaktivierung über einen alternativen weg

Country Status (13)

Country Link
US (3) US6333034B1 (de)
EP (1) EP1007092B1 (de)
JP (1) JP2001513576A (de)
AT (1) ATE335511T1 (de)
AU (1) AU756490B2 (de)
CA (1) CA2302317A1 (de)
DE (1) DE69835524T2 (de)
DK (1) DK1007092T3 (de)
ES (1) ES2270530T3 (de)
NO (1) NO20000935L (de)
NZ (1) NZ503033A (de)
PT (1) PT1007092E (de)
WO (1) WO1999010009A1 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6641571B2 (en) * 2000-01-05 2003-11-04 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Reduction of postoperative complications of cardiopulmonary bypass (CPB) surgery
PT1325033E (pt) 2000-10-10 2010-04-15 Genentech Inc Inibição da activação do complemento c5 para o tratamento e a prevenção da rejeição diferida de um xenoenxertos ou de uma rejeição vascular aguda
JP2004536138A (ja) * 2001-07-26 2004-12-02 アレクシオン ファーマシューティカルズ， インコーポレイテッド 認識機能を改善する方法
ES2198216B1 (es) * 2002-07-02 2005-04-16 Juan Carlos Instituto Cientifico Y Tecnologico De Navarra, S.A.(67%). Medio de cultivo de celulas madre-progenitoras autologas humanas y sus aplicaciones.
AU2003295600A1 (en) * 2002-11-14 2004-06-15 Dharmacon, Inc. Functional and hyperfunctional sirna
US7361339B2 (en) * 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US20070123466A1 (en) * 2003-05-13 2007-05-31 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Method of treating recurrent miscarriages
US7959919B2 (en) * 2003-11-19 2011-06-14 Novelmed Therapeutics, Inc. Method of inhibiting factor B-mediated complement activation
JP5137053B2 (ja) * 2004-02-10 2013-02-06 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト 抗ｂ因子抗体もしくはその抗原結合性フラグメント、それを含む組成物、抗原結合性ポリペプチド、および治療薬
WO2005094880A1 (en) * 2004-03-30 2005-10-13 Canadian Blood Services Method for treating autoimmune diseases with antibodies
BRPI0401765C1 (pt) * 2004-05-17 2011-03-15 Hy Biotecnologica Ltda método de enriquecimento de espermatozoides de mamìferos portadores de cromossomo x ou de cromossomo y
US7423128B2 (en) * 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
AU2006249835B2 (en) * 2005-05-26 2011-09-08 Musc Foundation For Research Development Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
CA2624393C (en) * 2005-11-04 2016-01-05 Genentech, Inc. Use of complement pathway inhibitors to treat ocular diseases
PL1976877T5 (pl) 2005-11-30 2017-09-29 Abbvie Inc Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
CN117903302A (zh) 2005-11-30 2024-04-19 Abbvie 公司 抗-Aβ球聚体抗体，其相关产品，生产所述抗体的方法，所述抗体的应用以及使用方法
EP3028716B1 (de) 2006-10-10 2020-09-16 Regenesance B.V. Komplementhemmung für verbesserte nervenregeneration
PL2907827T3 (pl) * 2006-11-02 2019-03-29 Genentech, Inc. Humanizowane przeciwciała przeciw czynnikowi D i ich zastosowanie
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2486928A1 (de) 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Verfahren zur Behandlung von Amyloidosen
AU2008251943B2 (en) 2007-03-14 2013-09-05 Alexion Pharmaceuticals, Inc. Humaneered anti-factor B antibody
US9745367B2 (en) * 2007-03-23 2017-08-29 Novelmed Theraputics, Inc. Alternative pathway specific antibodies for treating arthritis
WO2009029669A1 (en) 2007-08-27 2009-03-05 Novelmed Therapeutics, Inc. Method of inhibiting complement activation with factor bb specific antibodies
US20100263061A1 (en) * 2007-06-11 2010-10-14 The Trustees Of The University Of Pennsylvania Properdin Modulation of Alternative Pathway and Uses Thereof
US10131706B2 (en) 2007-08-27 2018-11-20 Novelmed Therapeutics, Inc. Anti-factor Bb antibodies
US20140127204A1 (en) 2010-09-03 2014-05-08 Novelmed Therapeutics, Inc. Anti-properdin antibodies
PL2262831T3 (pl) * 2008-03-03 2015-08-31 Novelmed Therapeutics Inc Przeciwciała przeciwko properdynie
US8664362B2 (en) 2008-03-03 2014-03-04 NovelMed Therapeutics Humanized and chimeric anti-properdin antibodies
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
US20110160636A1 (en) * 2008-09-10 2011-06-30 Rekha Bansal Device and method for inhibiting complement activation
WO2010057084A1 (en) * 2008-11-14 2010-05-20 Novelmed Therapeutics, Inc. Method of treating ischemia reperfusion injury
RS20120461A1 (en) 2009-07-02 2013-06-28 Musc Foundation For Research Development METHODS FOR STIMULATION OF LIVER REGENERATION
AU2011223660B2 (en) * 2010-03-02 2016-10-13 Novelmed Therapeutics, Inc. A method for inhibiting alternative pathway mediated disorders with anti-properdin antibodies that inhibit C5 interactions with properdin
AU2011224224B2 (en) * 2010-03-10 2015-07-09 Novelmed Therapeutics, Inc. Humanized and chimeric anti-properdin antibodies
CA2796339C (en) 2010-04-15 2020-03-31 Abbott Laboratories Amyloid-beta binding proteins
CA2808187A1 (en) 2010-08-14 2012-02-23 Abbvie Inc. Amyloid-beta binding proteins
AU2012272706B2 (en) 2011-06-22 2017-07-06 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
ES2701075T3 (es) 2011-07-01 2019-02-20 Univ Pennsylvania Anticuerpos antiproperdina y usos de estos
CA2859493A1 (en) 2011-12-21 2013-06-27 Novartis Ag Compositions and methods for antibodies targeting factor p
JP6262715B2 (ja) * 2012-04-03 2018-01-17 ノーベルメッド セラピューティクス インコーポレイテッド． ヒト化およびキメラ抗ｃ３因子抗体、ならびにその使用
EP2855529A4 (de) 2012-05-24 2015-12-09 Alexion Pharma Inc Humanisierte anti-faktor-b-antikörper
CN104870474B (zh) 2012-10-04 2019-03-12 诺沃姆德治疗公司 用于治疗溶血性疾病的旁路途径特异性抗体
ES2514165B1 (es) * 2013-03-27 2015-09-09 Consejo Superior De Investigaciones Científicas (Csic) Anticuerpo anti-factor b, composición farmacéutica útil para el tratamiento de enfermedades del complemento y sus aplicaciones
US10093978B2 (en) 2013-08-12 2018-10-09 Genentech, Inc. Compositions for detecting complement factor H (CFH) and complement factor I (CFI) polymorphisms
CR20160561A (es) 2014-05-01 2017-05-03 Genentech Inc Variantes del anticuerpo anti-factor d y sus usos
US10654932B2 (en) 2015-10-30 2020-05-19 Genentech, Inc. Anti-factor D antibody variant conjugates and uses thereof
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
WO2017127761A1 (en) 2016-01-20 2017-07-27 Vitrisa Therapeutics, Inc. Compositions and methods for inhibiting factor d
EP3275897A1 (de) * 2016-07-27 2018-01-31 Biotest AG Verfahren zur herstellung von immunoglobulinzusammensetzungen
US11007254B2 (en) 2016-10-17 2021-05-18 Musc Foundation For Research Development Compositions and methods for treating central nervous system injury
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
GB2583560A (en) 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
US11981727B2 (en) 2021-08-31 2024-05-14 Novelmed Therapeutics, Inc Monospecific and bispecific antibodies and antigen binding fragments thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4642284A (en) * 1983-06-13 1987-02-10 Scripps Clinic And Research Foundation Method and system for detection of complement pathway activation
US5434075A (en) * 1992-03-20 1995-07-18 Board Of Trustees Of The University Of Illinois Monoclonal antibody to a human MDR1 multidrug resistance gene product, and uses
WO1995025540A1 (en) 1994-03-23 1995-09-28 Alexion Pharmaceuticals, Inc. Method for reducing immune and hemostatic dysfunctions during extracorporeal circulation

Also Published As

Publication number Publication date
CA2302317A1 (en) 1999-03-04
WO1999010009A1 (en) 1999-03-04
ATE335511T1 (de) 2006-09-15
US20030198636A1 (en) 2003-10-23
EP1007092B1 (de) 2006-08-09
US20020015701A1 (en) 2002-02-07
US6333034B1 (en) 2001-12-25
EP1007092A1 (de) 2000-06-14
JP2001513576A (ja) 2001-09-04
PT1007092E (pt) 2006-12-29
NO20000935D0 (no) 2000-02-25
DE69835524T2 (de) 2007-04-05
NO20000935L (no) 2000-04-18
AU9203398A (en) 1999-03-16
AU756490B2 (en) 2003-01-16
ES2270530T3 (es) 2007-04-01
DK1007092T3 (da) 2006-10-02
NZ503033A (en) 2003-01-31

Similar Documents

Publication Publication Date Title
DE69835524D1 (de) Ein verfahren zur inhibierung der komplementaktivierung über einen alternativen weg
DE69830574D1 (de) Verbesserte verfahren zur herstellung von vernetzt verbrückten macropolycyclen
DE69818304D1 (de) Verfahren zur reduktion von oxiranyl-epothilonen zu olefinischen epothilonen
DE69418714D1 (de) Verfahren zur kryptographischer authentifizierung übertragener nachrichten unter verwendung von pseudo-zufallszahlen
ES2149514T3 (es) Procedimiento para la obtencion simultanea de capro-lactama y hexametilendiamina.
DE59809789D1 (de) Verfahren zur Herstellung von Propen
DE69203767T2 (de) Verfahren zur Herstellung von organischen Düngemitteln.
DE69613384D1 (de) Verfahren zur hydrocyanierung von organischen, ethylenisch ungesättigten verbindungen
DE69018178T2 (de) Verfahren zur Herstellung von Disilan.
DE69019753T3 (de) Verfahren zur verwendung von gashilfe während des giessens von kunststoffgegenständen.
DE59103454D1 (de) Verfahren zur Herstellung von feinteiligen, wasserlöslichen Polymerisaten.
DE69020172T2 (de) Verfahren zur Herstellung von epsilon-Caprolactam.
ATE268996T1 (de) Verbessertes formverfahren für konfektprodukte
DE69412559D1 (de) Verfahren zur Vergasung von organischen Materien
DE59702009D1 (de) Verfahren zur herstellung von 1,4,7,10-tetraazacyclododecan und dessen derivaten
EA199900741A1 (ru) Способ получения эпросартана
DE59000468D1 (de) Verfahren zur schnellen pruefung der wirksamkeit von agenzien auf mikroorganismen.
DE68924815D1 (de) Verfahren zur Haftung von aromatischen Polyamiden.
ATE235461T1 (de) Verfahren zur herstellung von 3-cyano-2,4- dihalogen-5-fluor-benzoesäuren
DE69019890T2 (de) Verfahren zur Produktion von der Spiroplasma sp. DNA Methylase.
DE69201168T2 (de) Verfahren zur Herstellung von Pfropfpolymere.
DE69603163D1 (de) VERFAHREN ZUR HERSTELLUNG VON HIV PROTEASE INHIBITOR AUSGEHEND VON (2S)-4-PICOLYL-2-PIPERAZIN-t-BUTYLCARBOXAMID
DE69001391D1 (de) Verfahren zur rueckfuehrung von bei der entklebung von lack, entstandenen abfaellen und endprodukt.
ATA82592A (de) Verfahren zur druckvergasung von organischen substanzen, z.b. kunststoffmischungen
DE59604072D1 (de) Verfahren zur Entsorgung von organischen Verbindungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee